Pirfenidone for IPF: pro/con debate; the 'con' viewpoint

被引：8
|
作者：
Raghu, Ganesh [1 ]
Thickett, David R. [2 ]
机构：
[1] Univ Washington, Div Pulm & Crit Care Med, Scleroderma Clin, UW Med Ctr, Seattle, WA 98195 USA
[2] Univ Birmingham, Ctr Translat Inflammat & Fibrosis Res, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England
来源：
THORAX | 2013年 / 68卷 / 07期
关键词：
IDIOPATHIC PULMONARY-FIBROSIS; INTERSTITIAL PNEUMONIA; CONTROLLED-TRIAL; DISEASE; INHIBITOR; REPAIR;
D O I：
10.1136/thoraxjnl-2011-201269
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：605 / 608
页数：4
相关论文
共 50 条
  • [21] Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF
    Milger, Katrin
    Kneidinger, Nikolaus
    Neurohr, Claus
    Reichenberger, Frank
    Behr, Juergen
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (04) : 1217 - 1221
  • [22] Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
    Balestro, Elisabetta
    Turato, Graziella
    Biondini, Davide
    Pavanello, Sofia
    Fraccaro, Alessia
    Rigobello, Chiara
    Bazzan, Erica
    Campisi, Manuela
    Baraldo, Simonetta
    Cosio, Manuel
    Saetta, Marina
    Spagnolo, Paolo
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [23] Endovascular Therapy for Thoracic Aneurysm Diseases: CON
    Elefteriades, John A.
    CARDIOLOGY CLINICS, 2010, 28 (02) : 413 - 417
  • [24] Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS
    Fernandez, Isis
    Sun, Na
    Wei, Mien
    Aichler, Michaela
    Welch, Axel
    Eickelberg, Oliver
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [25] Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone
    Sincholle, Francois
    Kolb, Martin
    Manganas, Helene
    El Keeb, Rabea
    Newton, Marc
    Monga, Neerav
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [26] Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
    Ronan, Nicola
    Khan, Kashif A.
    Subramaniam, Abirami
    McCarthy, Yvonne
    Burke, Louise
    Chelliah, A.
    Plant, Barry J.
    Henry, Michael T.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [27] Factors influencing best tolerated dose of pirfenidone (PFD) in patients with IPF
    Agrawal, Neha
    Vaidya, Preyas
    Shah, Ria
    Chavhan, Vinod
    Leuppi, Joerg
    Leuppi-Taegetmeyer, Anne
    Chhajed, Prashant
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [28] Treatment of Acute Cough Due to the Common Cold: Multi-component, Multi-symptom Therapy is Preferable to Single-Component, Single-Symptom Therapy-A Pro/Con Debate
    Eccles, Ronald
    Turner, Ronald B.
    Dicpinigaitis, Peter V.
    LUNG, 2016, 194 (01) : 15 - 20
  • [29] Pirfenidone improves survival in IPF: results from a real-life study
    Margaritopoulos, George A.
    Trachalaki, Athina
    Wells, Athol U.
    Vasarmidi, Eirini
    Bibaki, Eleni
    Papastratigakis, George
    Detorakis, Stathis
    Tzanakis, Nikos
    Antoniou, Katerina M.
    BMC PULMONARY MEDICINE, 2018, 18
  • [30] Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation
    Veit, Tobias
    Leuschner, Gabriela
    Sisic, Alma
    Ceelen, Felix
    Munker, Dieter
    Schmitzer, Magdalena
    Weig, Thomas
    Michel, Sebastian
    Schneider, Christian
    Meiser, Bruno
    Crispin, Alexander
    Neurohr, Claus
    Behr, Juergen
    Milger, Katrin
    Kneidinger, Nikolaus
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 (08) : 2358 - 2365
12345